Anixa Biosciences, Inc.ANIXNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank29
Studio
Year-over-Year Change

Year-over-year research & development expense growth

Percentile
P29
Within normal range
vs 3Y Ago
-2.5x
Contraction
Streak
1 yr
Consecutive declineDecelerating
PeriodValue
2025-20.72%
202434.12%
2023-28.85%
20228.29%
202141.28%
2020-19.95%
2019-19.66%
2018326.47%
20172.64%
2016118.79%